Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Diabetes / Metabolic Rheumatology Gastroenterology Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT07516496

Metabolic Phenotyping in vEDS

Metabolic Phenotyping in vEDS — Recruiting • Cardiology / Cardiovascular • NCT07516496.

📅 08 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07516496
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Start
2026-03-05
ClinicaliQ Trial Snapshot
  • Metabolic Phenotyping in vEDS — Recruiting • Cardiology / Cardiovascular • NCT07516496.
  • This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a….
  • Sponsor: Cambridge University Hospitals NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This research study will investigate whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way their body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, there is some early evidence that it may also affect fat tissue and increase the risk of problems such as insulin resistance (where the body does not respond properly to…

Eligibility Snapshot
  • : * Age over 18 years * Confirmed pathogenic or likely pathogenic COL3A1 mutation with vascular Ehlers-Danlos syndrome * Capacity to provide informed consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
CPD
Cardiovascular Risk Reduction — Latest Evidence 2024
Cardiology / Cardiovascular · 1.5 CPD hours · 25 Mar 2026
Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification. Apply statin, ezetimibe, PCSK9 inhibitor and inclisiran pathways in…
Complete CPD →
Clinical Brief
People searching NHS advice on high blood pressure skyrocketed last year
Cardiology / Cardiovascular · NHS England · 21 Feb 2026
The number of people searching for trusted NHS advice on high blood pressure surged in 2025 with hundreds of thousands of extra…
View brief →
Guideline
Heart Failure: Diagnosis and Management (NICE NG106)
Cardiology / Cardiovascular · 27 Mar 2026
Use NT-BNP or BNP testing in primary care to rule out heart failure; refer urgently to secondary care if elevated with compatible…
View guideline →
Guideline
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Cardiology / Cardiovascular · 30 Mar 2026
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies…
View guideline →
Guideline
Cardiovascular Disease: Risk Assessment and Reduction (NICE NG238)
Cardiology / Cardiovascular · 27 Mar 2026
Perform CVD risk assessment using Framingham equation or QRISK3 in all adults aged 40–74 years; initiate atorvastatin 20 mg daily if 10-year…
View guideline →